The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place in Chicago, USA, from April 25 to 30. The recently released conference abstracts highlight the strong presence of Chinese biopharmaceutical companies in the field of antibody-drug conjugates (ADCs). At this year’s conference, Chinese pharmaceutical companies dominate the ADC field, presenting […]
On November 20, 2024, Jazz Pharmaceuticals announced that the bispecific antibody Zanidatamab had received accelerated approval from the FDA for the treatment of adult patients with previously treated, unresectable, or metastatic HER2-positive (HER2+, defined as IHC 3+) biliary tract cancer (BTC). Zanidatamab is the first approved HER2-targeting bispecific antibody with dual epitope specificity. On December […]
1. About (G4S)n Linkers The (G4S)n linker refers to a flexible linker composed of one or more repeating units of G4S (Gly-Gly-Gly-Gly-Ser). Due to its moderate length and flexibility, this linker is widely used in molecular designs requiring the connection of two proteins or peptides. 1.1 Structure Amino Acid Sequence: (Gly-Gly-Gly-Gly-Ser)n Repeating Modules: Composed of […]
1. About Synthetic Nanodisc The lipid composition of traditional membrane scaffold protein (MSP) nanodiscs often differs from that of natural cell membranes, which can lead to deviations in membrane protein properties compared to their native environment. To address this limitation, DIMA has developed the Synthetic Nanodisc platform. This innovative technology enables the direct preparation of […]
Prostate-specific membrane antigen (PSMA) is a pivotal molecular target in the treatment and diagnosis of prostate cancer (PCa). Over the past two decades, extensive research has illuminated its unique molecular characteristics, paving the way for advanced diagnostic and therapeutic approaches. PSMA-targeted imaging techniques, particularly positron emission tomography (PET) radiotracers, have demonstrated exceptional sensitivity in detecting […]
Recent statistics reveal a growing interest in targeting GDF-15 for therapeutic interventions. Currently, there are several drugs targeting GDF-15, with some facing challenges or discontinuation. Of the remaining candidates, many are in early development stages, including preclinical and clinical trials. Specifically, a few drugs have advanced to Phase 1 and Phase 2 clinical trials. These […]
Recent advancements in the field of nuclear medicine have highlighted the significance of B-Cell Maturation Antigen (BCMA) as a pivotal target for the diagnosis and treatment of Multiple Myeloma (MM). In a groundbreaking study published in the European Journal of Nuclear Medicine and Molecular Imaging, a collaborative effort by the molecular imaging team at the First Affiliated Hospital of Jinan University and the Chinese Academy of Medical Sciences has demonstrated the efficacy of the radiolabeled antibody [89Zr]Zr-DFO-BCMAh230430 in non-invasive PET imaging of MM. This research represents a significant step forward in the development of specific immuno-PET probes targeting BCMA, which is highly expressed in malignant plasma cells.
In 2024, the radiopharmaceutical sector has seen a flurry of activity in mergers and acquisitions. In March, AstraZeneca announced a $2.4 billion acquisition of Fusion Pharmaceuticals, a biopharmaceutical company focused on developing next-generation radiolabeled conjugates (RDCs). In April, Novartis invested nearly $2.71 billion to partner with PeptiDream to co-develop several macrocyclic-targeted conjugate radiopharmaceuticals. In May, Novartis made […]
On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and commercialize uliledlimab in Greater China. This partnership, valued at approximately €213 million (around 1.7 billion RMB), aims to leverage Sanofi’s expertise in oncology to accelerate the development and commercialization of uliledlimab, which is an innovative CD73 monoclonal antibody independently developed […]
On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a potentially first-in-class antibody-drug conjugate (ADC) targeting HER3, has met its primary endpoint for progression-free survival (PFS) in the Phase 3 lung cancer trial HERTHENA-Lung02. This treatment demonstrated statistically significant improvement compared to platinum-based chemotherapy combined with pemetrexed induction and pemetrexed […]